DOMO:NASDAQDomo, Inc. Analysis
Data as of 2026-06-21 - not real-time
$2.42
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Domo’s stock is trading at roughly $2.42, well beneath the DCF‑derived fair value of about $9.4, implying approximately 80 % upside on paper. However, the 20‑day and 50‑day SMAs sit above $3.3, and the MACD line remains in bearish territory, confirming a down‑trend on the charts. The RSI of 36.7 suggests the shares are not yet oversold, while the 30‑day volatility exceeds 160 %, flagging extreme price swings. A beta near 3 underscores that Domo moves almost three times the market, amplifying both upside and downside. The current support at $1.84 and resistance near $4.66 frame a narrow trading range that the price has struggled to break upward.
On the fundamentals side, revenue is flat year‑over‑year at $79 M and margins are still negative, but free cash flow of $40 M and gross retention of 86.7 % show improving operational efficiency. The company disclosed a potential strategic transaction, which management claims is the “best path forward,” adding a possible catalyst despite the lack of guidance. Analysts remain optimistic, with a consensus “buy” rating and target prices around $4.30, reflecting belief in the long‑run value of the platform. Yet the balance sheet is strained, featuring $148 M of debt against negative equity and a recent 35 % share‑price plunge after earnings. Given the mix of deep discount, high volatility, and near‑term uncertainty, we advise caution in the short run but see moderate upside if the strategic deal materializes. Consequently, we recommend a short‑term sell, a medium‑term buy, and a long‑term hold to capture upside while managing risk.
On the fundamentals side, revenue is flat year‑over‑year at $79 M and margins are still negative, but free cash flow of $40 M and gross retention of 86.7 % show improving operational efficiency. The company disclosed a potential strategic transaction, which management claims is the “best path forward,” adding a possible catalyst despite the lack of guidance. Analysts remain optimistic, with a consensus “buy” rating and target prices around $4.30, reflecting belief in the long‑run value of the platform. Yet the balance sheet is strained, featuring $148 M of debt against negative equity and a recent 35 % share‑price plunge after earnings. Given the mix of deep discount, high volatility, and near‑term uncertainty, we advise caution in the short run but see moderate upside if the strategic deal materializes. Consequently, we recommend a short‑term sell, a medium‑term buy, and a long‑term hold to capture upside while managing risk.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- bearish technical indicators
- recent earnings miss and share price plunge
- balance sheet stress and high debt
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- substantial valuation discount to DCF
- potential strategic transaction catalyst
- improving cash flow and retention metrics
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- long‑term growth of data analytics market
- high beta and volatility remain
- uncertain outcome of strategic deal
Key Metrics & Analysis
Financial Health
Revenue Growth-0.90%
Profit Margin-17.43%
P/E Ratio22.4
ROA-10.46%
P/B Ratio-0.6
Op. Cash Flow$9.2M
Free Cash Flow$40.6M
Industry P/E38.1
Technical Analysis
TrendBearish
RSI36.7
Support$1.84
Resistance$4.66
MA 20$3.40
MA 50$3.49
MA 200$7.89
MACDBearish
VolumeIncreasing
Fear & Greed Index91.46
Valuation
Fair Value$9.42
Target Price$4.33
Upside/Downside79.06%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.90
Volatility168.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.